Clinical characteristics of sarcoma cases in which long-term disease control was achieved with trabectedin treatment: A retrospective study
Akihiro Ohmoto(Japanese Foundation For Cancer Research), Shunji Takahashi(Japanese Foundation For Cancer Research), Junichi Tomomatsu(The Cancer Institute Hospital), Keiko Hayakawa(Cancer Institute (WIA)), Ryosuke Oki(Tokushima University), Masanori Saito(Japanese Foundation For Cancer Research), Naoki Fukuda(The Cancer Institute Hospital), Makiko Ono(The Cancer Institute Hospital), Kenji Nakano(National Center for Global Health and Medicine), Seiichi Matsumoto(Fukuda Denshi (Japan)), Taisuke Tanizawa(Japanese Foundation For Cancer Research), Shohei Udagawa(Japanese Foundation For Cancer Research), Mayu Yunokawa(Japanese Foundation For Cancer Research), Xiaofei Wang(Duke University), Naomi Hayashi(The Cancer Institute Hospital), Yusuke Minami(Hokkaido University), Keisuke Ae(The Cancer Institute Hospital), Tetsuya Urasaki(Japanese Foundation For Cancer Research), Hirotaka Suto(Japanese Foundation For Cancer Research), Yasuyoshi Sato(The Cancer Institute Hospital)
Cited by 3
Related Papers
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2021|412
Clear Cell Sarcoma of Soft Tissue
|The American Journal of Surgical Pathology|2008|283
Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A
|Proceedings of the National Academy of Sciences|2018|264